Lorna Harries
Professor - Analytics, Operations Management & Director- Research for Science, Innovation, Technology & Entrepreneurship University of Exeter Medical School
Professor Lorna Harries is Chief Scientific Officer at SENISCA and Professor of Molecular Genetics at the University of Exeter Medical School. She leads pioneering research targeting age-related changes in alternative splicing, an emerging, druggable hallmark of ageing, with therapeutic implications for fibrotic diseases such as IPF. With over 135 peer-reviewed publications, her work explores RNA-mediated mechanisms of disease and the role of cellular senescence in chronic age-related conditions. A recognized leader in the ageing and RNA biology fields, she serves as Secretary of the British Society for Research on Ageing and is a frequent keynote speaker at international scientific conferences.
Seminars
Panel Discussion Points:
- Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
- What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
- Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
- How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
- Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?
- SENISCA have discovered a new and druggable cause of cellular ageing, dysregulated mRNA processing
- We have designed an RNA therapeutic with a unique MoA capable of restoring levels of splicing regulators back within their homeostatic limits for selective reprogramming of senescent cells
- We have demonstrated efficacy for our new approach in primary human IPF patient cells and in precision cut lung slices from patients with IPF and other interstitial fibrosis disorders
